as a result of our performance in the underlying business and the contribution from covid-related items, we are raising our adjusted earnings per diluted share guidance to $num-one to $num-two.
as a result of our strong year-to-date performance and our outlook for the remainder of the fiscal year, we are raising and narrowing our previous adjusted earnings per share guidance range to $num-one to $num-two, which is above our previous range of $num-three to $num-four.
we're pleased to report a strong third quarter with total company revenues of $num-one billion and an adjusted earnings per diluted share of $num-two, ahead of our expectations.
for fiscal year-eight, we currently anticipate approximately $num-one of adjusted earnings per diluted share accretion related to the held-for-sale accounting based on their current estimated close date for the phoenix group transaction.
fiscal year-seven adjusted earnings per diluted share guidance also includes $num-one to $num-two of contribution attributable to the following items: $num-three to $num-four related to the u.s. government's covid vaccine distribution; $num-five to $num-six related to the kitting, storage and distribution of ancillary supplies; $num-seven to $num-eight related to covid tests; and the fiscal year-six impairments for ppe and related products, which is an increase from the previous range of $num-nine to $num-seven; and approximately $num-ten from gains and losses associated with mckesson ventures' equity investments, which are within our corporate segment.
the $num-one adjusted earnings per diluted share increased includes the following: approximately $num-two driven by strong underlying business performance and operating leverage, approximately $num-three related to covid tests, approximately $num-three related to held-for-sale accounting and reduced opioid litigation expenses, and approximately $num-four related to mci interest expense and lower weighted average shares outstanding.
third quarter adjusted earnings per diluted share was $num-one, an increase of num-two% compared to the prior year.
this is from the previous range of $num-one to $num-two.
as a result, we now anticipate returning approximately $num-one billion to shareholders through share repurchases in fiscal year-seven.
a full list of our fiscal year-seven assumptions can be found on slide-num through num-one.
for the international segment, we anticipate $num-one of adjusted earnings per diluted share accretion in the first half of fiscal year-eight related to the held-for-sale accounting based on the current estimated close date for the phoenix group transaction.
in our prescription technology solutions segment, we anticipate revenue growth of num-one% to num-two% and adjusted operating profit growth of num-three% to num-four%.
in the u.s. pharmaceutical segment, we anticipate revenue to increase num-one% to num-two% and adjusted operating profit to deliver num-one% to num-three% growth over the prior year.
our outlook includes $num-one to $num-two related to the contribution from the u.s. government's distribution of ancillary supply kits and storage programs and $num-three to $num-four related to the net impact of covid tests and ppe impairments and related products.
with this increased authorization, the completed sales of the austrian business and remaining share in the german joint venture and the anticipated fiscal fourth quarter closure of the sale of the u.k. business, we anticipate executing share repurchases of up to $num-one billion in the fourth quarter.
we reported a gaap-only after-tax charge of $num-one million related to the sale of retail and distribution businesses in the u.k. to account for the remeasurement of the net assets to the lower carrying amount of fair value less cost to sell.